Early diagnosis can protect working caregivers from lost pay and crisis care, but access is uneven and families carry most of the cost. The 2026 National Institute on Ageing report treats this as a care access problem, with delayed diagnosis and weak follow-up support. Early dementia diagnosis means finding cognitive decline and its likely cause while planning and work are still possible. Diagnosis economics means who pays for testing, time off, daily help, and medical care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why do so many cases stay undiagnosed?
- What does dementia cost working caregivers?
- Can a blood test improve access?
- What can working caregivers do now?
Why do so many cases stay undiagnosed?
Canada has an estimated 772,000 people living with dementia, while a cited global undiagnosed share of 61.7% suggests up to 2 million Canadians may be affected without a diagnosis. That gap matters for workers who need a clear diagnosis to request leave, services, and workplace changes.
The National Institute on Ageing names five barriers in its July 2026 NIA report: diagnostic delays, primary-care gaps, inconsistent post-diagnostic supports, poor coordination, and inequitable care. For a working adult, a long wait for referral can mean months of missed shifts and night supervision.
What does dementia cost working caregivers?
The NIA-funded U.S. Cost of Dementia Project puts total 2026 U.S. dementia costs at $818 billion for 5.7 million adults age 51 and older and 5.2 million care partners, according to the USC Schaeffer Center analysis.
That total includes $237 billion for 6.8 billion hours of unpaid caregiving, $222 billion for medical and long-term care, plus $23 billion in forgone earnings by patients and working-age care partners. A separate Alzheimer's Association estimate places health and long-term-care payments at $409 billion, excluding unpaid care, with about $405,262 in lifetime cost per person and about 70% borne by families. The pattern is direct: formal care is costly, unpaid hours are large, and earnings fall when care collides with work.
Can a blood test improve access?
The U.S. Food and Drug Administration cleared Lumipulse G pTau217/ß-Amyloid 1-42 plasma ratio on May 16, 2025 for adults 55 and older with signs and symptoms, as stated in the FDA approval notice.
It was the first blood test aiding amyloid-plaque detection with less reliance on PET scans. Less reliance on PET scans can reduce travel, scheduling, and referral hurdles for employed caregivers. A blood test does not replace clinical judgment, staging, care planning, or support after diagnosis.
What can working caregivers do now?
Ask the primary-care clinic about referral routes, wait times, and what records to bring from work absences and daily tasks. Keep one folder with symptom dates, medicines, test results, and names of each provider involved.
Enrolled dementia programs in the CMS 8-year GUIDE demonstration from July 1, 2024 through June 30, 2032 receive payment for coordination and can reimburse up to $2,500 yearly per patient for respite for qualifying caregivers. Ask a clinic whether it participates and what caregiver qualifies for.
- Track weekly care hours, missed work, and paid help for one month
- Ask what post-diagnostic support is offered locally, and who coordinates it
- Ask about respite options before exhaustion forces time off
- Bring another family member to the results visit to record next steps
You Might Also Like
- Safety Questions After the 2026 LiBBY Dementia Trial: How Spouses and Partners Can Avoid Overreading the Headline
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: How Spouses and Partners Can Avoid Overreading the Headline
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: How Spouses and Partners Can Avoid Overreading the Headline
